Measurement of behaviour disturbance, non-cognitive symptoms and quality of life

2010 ◽  
pp. 75-85
Author(s):  
Ajit Shah ◽  
Ian Nnatu
Keyword(s):  
Quality Of Life ◽  
Cognitive Symptoms

scholarly journals Examining Normative Reference Values and Item-Level Symptom Endorsement for the Quality of Life in Neurological Disorders (Neuro-QoL™) v2.0 Cognitive Function-Short Form

2020 ◽  
Author(s):  
Grant L Iverson ◽  
Eric J Connors ◽  
Jacqueline Marsh ◽  
Douglas P Terry
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Cognitive Function ◽  
Neurological Disorders ◽  
Short Form ◽  
Cognitive Symptoms ◽  
Cognitive Difficulties ◽  
Base Rates ◽  
Item Level

Abstract Objective We examined the normative reference values, item-level symptom endorsement, internal consistency reliability, and the base rates of symptoms endorsed for the quality of life in neurological disorders (Neuro-QoL™) v2.0 Cognitive Function-Short Form. Method The Neuro-QoL™ v2.0 Cognitive Function-Short Form measures subjective cognitive difficulties. The normative sample from the U.S. general population was stratified by gender, education, health status, self-reported diagnosis of depression or anxiety, and recent mental health symptoms (i.e., endorsed frequent anxiety or depression symptoms in the last week). Results A cohort of 1,009 adults completed this scale and their mean score was 32.60 (SD = 6.89). The base rates of those who reported zero cognitive symptoms were consistently higher among the healthy samples (healthy men = 79.2%; all men = 63.9%; healthy women = 90.2%; all women = 80.0%). Endorsing three or more cognitive symptoms was more common in the mental health subgroups for both men (full men’s sample [n = 493] = 17.6%; depression subgroup [n = 70] = 30.0%; anxiety subgroup [n = 61] = 29.5%; mental subhealth group [n = 70] = 38.6%) and women (full women’s sample [n = 516] = 7.4%; depression subgroup [n = 123] = 13.0%; anxiety subgroup [n = 103] = 12.6%; mental health subgroup [n = 101] = 14.9%). Internal consistency was measured using Cronbach’s α and ranged from 0.87 to 0.94 across groups. Conclusions The Neuro-QoL™ v2.0 Cognitive Function-Short Form is a brief, efficient, and reliable measure of perceived cognitive difficulties. As expected, individuals with a favorable overall health and quality of life reported less cognitive symptoms than the total sample, whereas individuals with mental health difficulties reported more. These normative values and base rates stratified by gender, overall health, and mental health status may be useful when interpreting this measure in clinical practice.

scholarly journals Factors associated with quality of life in elderly undertaking literacy programs

2014 ◽  
Vol 8 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Bruna Rodrigues dos Santos ◽  
Sofia Cristina Iost Pavarini ◽  
Allan Gustavo Brigola ◽  
Fabiana de Souza Orlandi ◽  
Keika Inouye
Keyword(s):  
Quality Of Life ◽  
Social Inclusion ◽  
Geriatric Depression Scale ◽  
Depression Scale ◽  
Sociodemographic Factors ◽  
Literacy Programs ◽  
Cognitive Symptoms ◽  
The Social ◽  
Proportional Relationship

ABSTRACT Increased life expectancy has led to a significant number of elderly enrolling on Youth and Adult Education programs (YAE). These individuals leave inactivity and negative aspects of aging in search of opportunities for social inclusion. Objective: To evaluate the influence of sociodemographic factors and depressive and cognitive symptoms on quality of life (QL) of elderly attending the YAE of São Carlos city in São Paulo state. Methods: A descriptive and quantitative study approved by the Research Ethics Committee of São Carlos Federal University was conducted. The sample comprised all elderly undertaking the YAE literacy program in 2012. The instruments used were the Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), WHOQOL-bref and WHOQOL-old, and a sociodemographic instrument. Results: We interviewed 23 elderly, predominantly females (91.3%) in the early stages of old age (69.6%). The number of years of YAE study showed no correlation with cognition scores obtained on the MMSE or with QL domains. However, scores on the GDS had a moderate inverse relationship with total scores for the Physical (p<0.01), Sensory Functioning (p<0.05), Independence (p<0.01), Past, Present and Future Activities (p<0.05), Social Participation (p<0.01), and Intimacy (p<0.05) QV domains, and a strong inversely proportional relationship with the Social Relationships QV domain (p<0.01). Scores attained on the MMSE showed a moderate and direct relationship with total scores on the Independence QL domain (p=0.001). Conclusion: Elderly on literacy programs have average quality of life scores. Several QL domains are influenced by depression and cognitive symptoms.

scholarly journals Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study

2015 ◽  
Vol 33 (34) ◽  
pp. 4085-4092 ◽  
Author(s):  
Janette L. Vardy ◽  
Haryana M. Dhillon ◽  
Gregory R. Pond ◽  
Sean B. Rourke ◽  
Tsegaye Bekele ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Verbal Learning ◽  
Controlled Study ◽  
Cognitive Symptoms ◽  
Anxiety Depression ◽  
Prospective Longitudinal

Purpose Cognitive dysfunction is reported in people with cancer. Therefore, we evaluated longitudinal changes in cognitive function and underlying mechanisms in people with colorectal cancer (CRC) and healthy controls (HCs). Patients and Methods Participants completed cognitive assessments and questionnaires reporting cognitive symptoms, fatigue, quality of life, and anxiety/depression at baseline (before chemotherapy, if given) and 6, 12, and 24 months. Blood tests included cytokines, clotting factors, apolipoprotein E genotype, and sex hormones. Primary end point was overall cognitive function measured by the Global Deficit Score at 12 months. Results We recruited 289 patients with localized CRC (173 received chemotherapy; median age, 59 years; 63% male), 73 patients with limited metastatic/recurrent CRC, and 72 HCs. Cognitive impairment was more frequent in patients with localized CRC than HCs at baseline (43% v 15%, respectively; P < .001) and 12 months (46% v 13%, respectively; P < .001), with no significant effect of chemotherapy. Attention/working memory, verbal learning/memory, and complex processing speed were most affected. Cognitive impairment was similar in patients with localized and metastatic CRC. Cytokine levels were elevated in patients with CRC compared with HCs. There was no association between overall cognitive function and fatigue, quality of life, anxiety/depression, or any blood test. Cognitive symptoms at 12 months were reported in 25% of patients with localized CRC versus 17% of HCs (P = .19). More participants who received chemotherapy had cognitive symptoms at 6 months (32%) versus those who did not (16%; P = .007), with no significant difference at 12 months (29% v 21%, respectively; P = .19). Objective cognitive function was only weakly associated with cognitive symptoms. Conclusion Patients with CRC had substantially more cognitive impairment at every assessment than HCs, with no significant added effect of chemotherapy. Mechanisms of cognitive impairment remain unknown.

scholarly journals Long-Term Cognitive Dysfunction in Cancer Survivors

2021 ◽  
Vol 8 ◽  
Author(s):  
Zuzana Országhová ◽  
Michal Mego ◽  
Michal Chovanec
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Cognitive Impairment ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Cognitive Symptoms ◽  
Cognitive Changes

Cancer-related cognitive impairment (CRCI) is a frequent side effect experienced by an increasing number of cancer survivors with a significant impact on their quality of life. Different definitions and means of evaluation have been used in available literature; hence the exact incidence of CRCI remains unknown. CRCI can be described as cognitive symptoms reported by cancer patients in self-reported questionnaires or as cognitive changes evaluated by formal neuropsychological tests. Nevertheless, association between cognitive symptoms and objectively assessed cognitive changes is relatively weak or absent. Studies have focused especially on breast cancer patients, but CRCI has been reported in multiple types of cancer, including colorectal, lung, ovarian, prostate, testicular cancer and hematological malignancies. While CRCI has been associated with various treatment modalities, including radiotherapy, chemotherapy, hormone therapy and novel systemic therapies, it has been also detected prior to cancer treatment. Therefore, the effects of cancer itself with or without the psychological distress may be involved in the pathogenesis of CRCI as a result of altered coping mechanisms after cancer diagnosis. The development of CRCI is probably multifactorial and the exact mechanisms are currently not completely understood. Possible risk factors include administered treatment, genetic predisposition, age and psychological factors such as anxiety, depression or fatigue. Multiple mechanisms are suggested to be responsible for CRCI, including direct neurotoxic injury of systemic treatment and radiation while other indirect contributing mechanisms are hypothesized. Chronic neuroinflammation mediated by active innate immune system, DNA-damage or endothelial dysfunction is hypothesized to be a central mechanism of CRCI pathogenesis. There is increasing evidence of potential plasma (e.g., damage associated molecular patterns, inflammatory components, circulating microRNAs, exosomes, short-chain fatty acids, and others), cerebrospinal fluid and radiological biomarkers of cognitive dysfunction in cancer patients. Discovery of biomarkers of cognitive impairment is crucial for early identification of cancer patients at increased risk for the development of CRCI or development of treatment strategies to lower the burden of CRCI on long-term quality of life. This review summarizes current literature on CRCI with a focus on long-term effects of different cancer treatments, possible risk factors, mechanisms and promising biomarkers.

scholarly journals Association of Motor and Cognitive Symptoms with Health-Related Quality of Life and Caregiver Burden in a German Cohort of Advanced Parkinson’s Disease Patients

2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
M. Klietz ◽  
T. Schnur ◽  
S. Drexel ◽  
F. Lange ◽  
A. Tulke ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Caregiver Burden ◽  
Motor Symptoms ◽  
Cognitive Symptoms ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Parkinson’s disease (PD) is a chronic progressive movement disorder with severe reduction in patients’ health-related quality of life (HR-QoL). Motor and cognitive symptoms are especially linked with decreased PD patients’ HR-QoL. However, the relationship of these symptoms to caregiver burden is relatively unclear. Influence of the Montreal Cognitive Assessment scale (MoCA) as a cognitive screening tool and Movement Disorders Society Unified Parkinson’s disease Rating Scale MDS-UPDRS symptoms in relation to patients’ HR-QoL and caregivers` burden was analyzed. PD patients (n = 124) completed MDS-UPDRS, MoCA, and the PD questionnaire 8 (PDQ-8) as a measure of quality of life. Caregivers (n = 78) were assessed by the PD caregiver burden inventory (PDCB). PDQ-8 and PDCB scores were regressed on MDS-UPDRS subscales and MoCA subscores. PDQ-8 correlated with attention (R2 0.1282; p<0.001) and executive (R2 0.0882; p 0.001) MoCA subscores and all parts of the MDS-UPDRS. PDCB correlated most strongly with MDS-UPDRS part III motor symptoms (R2 0.2070; p<0.001) and the MoCA attention subscore (R2 0.1815; p<0.001). While all facets of PD symptoms assessed by the MDS-UPDRS relate to PD patients’ quality of life, motor symptoms are the most relevant factor for the prediction of caregiver burden. In addition, patients’ attentional symptoms seem to affect not only them, but also their caregivers. These findings show the potential of a detailed analysis of MDS-UPDRS and MoCA performance in PD patients.

scholarly journals Quality of life of irradiated brain tumor survivors treated with donepezil or placebo: Results of the WFU CCOP research base protocol 91105

2017 ◽  
Vol 5 (2) ◽  
pp. 114-121 ◽  
Author(s):  
Michelle J Naughton ◽  
L Douglas Case ◽  
Ann Peiffer ◽  
Michael Chan ◽  
Volker Stieber ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Functional Assessment ◽  
Positive Impact ◽  
Well Being ◽  
Cognitive Symptoms ◽  
Brain Irradiation ◽  
Chronic Illness Therapy ◽  
Related Quality ◽  
Health Related

Abstract Background The health-related quality of life (HRQL) and fatigue of brain cancer survivors treated with donepezil or placebo for cognitive symptoms after radiation therapy were examined. Methods One hundred ninety-eight patients who completed >30 Gy fractionated whole or partial brain irradiation at least 6 months prior to enrollment were randomized to either placebo or donepezil (5 mg for 6 weeks followed by 10 mg for 18 weeks) in a phase 3 trial. A neurocognitive battery, the Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue, was administered at baseline, 12 weeks, and 24 weeks. Results At 12 weeks, donepezil resulted in improvements in only emotional functioning (P = .04), with no significant effects at week 24. Associations by level of baseline cognitive symptoms (above or below the median score of the baseline FACT-Br “additional concerns/brain” subscale), indicated that participants with more baseline symptoms who received donepezil versus placebo, showed improvements in social (P = .02) and emotional well-being (P = .038), other concerns/brain (P = .003) and the FACT-Br total score (P = .004) at 12 weeks, but not 24 weeks. However, participants with fewer baseline symptoms randomized to donepezil versus placebo reported lower functional well-being at both 12 (P = .015) and 24 weeks (P = .009), and greater fatigue (P = .02) at 24 weeks. Conclusions The positive impact of donepezil on HRQL was greater in survivors reporting more baseline cognitive symptoms. Donepezil had significantly worse effects on fatigue and functional well-being among participants with fewer baseline symptoms. Future interventions with donepezil should target participants with more baseline cognitive complaints to achieve greater therapeutic impact and lessen potential side effects of treatment.

Sign in / Sign up

Export Citation Format

Share Document